Matt Hoffman - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Matt Hoffman's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Matt Hoffman
Verified
Associate Editorial Director, NeurologyLive
Cranbury
Beats
Mental Health
Content
By Matt Hoffman Verified| NeurologyLive Verified The FDA has approved vutrisiran (Amvuttra; Alnylam Pharmaceuticals) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.1This expanded indication makes vutrisiran both the first and the only FDA-approved therapy for both the cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
Comorbidity Burden Is Associated With Increased Adverse Events, DMT Discontinuation in MS Clinical Trials
By Matt Hoffman Verified| NeurologyLive Verified Among a large group of patients with multiple sclerosis (MS), a higher rate of discontinuation of disease-modifying therapies (DMTs) was associated with the presence of 2 or more existing comorbidities, with psychiatric and cardiometabolic disorders showing particularly increased rates of early discontinuation.1 Additionally, data suggest that greater comorbidity burden was associated with higher rates of adverse events of interest (AESIs) such as infection, treatment-emergent autoimmune...
By Matt Hoffman Verified| NeurologyLive Verified The FDA has approved vutrisiran (Amvuttra; Alnylam Pharmaceuticals) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.1This expanded indication makes vutrisiran both the first and the only FDA-approved therapy for both the cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
Company Info
NeurologyLive
NeurologyLive is a multimedia platform focused on delivering the latest news and insights in the field of neurology. It serves as a valuable resource for healthcare professionals, particularly those treating neurological diseases. The platform offers a combination of print and digital media, ensuring that busy clinicians stay informed about significant developments in neurology. The services provided by NeurologyLive include breaking news on drug approvals, clinical trials, and emerging trends in neurological care. It features expert interviews with leading neurologists, offering insights into the latest research and clinical practices. The use of multimedia content makes the information accessible and engaging for its audience. NeurologyLive targets healthcare professionals such as neurologists, clinicians, and researchers. It has established strategic partnerships with organizations like the Consortium of Multiple Sclerosis Centers, enhancing its credibility and reach within the neurology community. Its comprehensive coverage and expert engagement position NeurologyLive as a trusted source for the latest developments in the field.
Cranbury, United States
+1 609-716-7777
Founded: 2018